LATHAM & WATKINS LLP

September 20, 2007

VIA EDGAR AND FACSIMILE

Securities and Exchange Commission Division of Corporation Finance 100 First Street, N.E. Washington, D.C. 20549

Attn: Tim Buchmiller Senior Counsel Mail Stop 6010

Re: Amgen Inc.

Definitive Proxy Statement Filed March 22, 2007 File Number: 000-12477

Dear Mr. Buchmiller:

On behalf of our client, Amgen Inc. (the "Company"), we confirm receipt of the comment letter to Mr. Kevin W. Sharer, the Company's Chief Executive Officer, dated August 21, 2007, from the Staff of the Division of Corporation Finance of the Securities and Exchange Commission, concerning the above referenced filing. We are writing this letter to confirm that the Company anticipates submitting its response to the comment letter on or before October 15, 2007. The extension will enable the Company's Compensation and Management Development Committee to review the draft responses to the comment letter at the Committee's next regularly scheduled meeting to be held on October 2, 2007 and will enable management to reflect any views of the Committee in the comment letter response.

Please call me at 714-755-8261 if you have any questions regarding this letter.

Sincerely,

/s/ Regina M. Schlatter

Regina M. Schlatter of LATHAM & WATKINS LLP

FIRM / AFFILIATE OFFICES

www.lw.com

650 Town Center Drive, 20th Floor Costa Mesa, California 92626-1925 Tel: +714.540.1235 Fax: +714.755.8290

Barcelona New Jersey
Brussels New York

Chicago Northern Virginia Frankfurt Orange County

Hamburg Paris
Hong Kong San Diego
London San Francisco
Los Angeles Shanghai
Madrid Silicon Valley
Milan Singapore
Moscow Tokyo

Munich Washington, D.C.